Literature DB >> 19726674

Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity.

Yasuhiro Nishiyama1, Stephanie Planque, Yukie Mitsuda, Giovanni Nitti, Hiroaki Taguchi, Lei Jin, Jindrich Symersky, Stephane Boivin, Marcin Sienczyk, Maria Salas, Carl V Hanson, Sudhir Paul.   

Abstract

We describe murine monoclonal antibodies (mAbs) raised by immunization with an electrophilic gp120 analog (E-gp120) expressing the rare ability to neutralize genetically heterologous human immunodeficiency virus (HIV) strains. Unlike gp120, E-gp120 formed covalent oligomers. The reactivity of gp120 and E-gp120 with mAbs to reference neutralizing epitopes was markedly different, indicating their divergent structures. Epitope mapping with synthetic peptides and electrophilic peptide analogs indicated binary recognition of two distinct gp120 regions by anti-E-gp120 mAbs, the 421-433 and 288-306 peptide regions. Univalent Fab and single chain Fv fragments expressed the ability to recognize both peptides. X-ray crystallography of an anti-E-gp120 Fab fragment revealed two neighboring cavities, the typical antigen-binding cavity formed by the complementarity determining regions (CDRs) and another cavity dominated by antibody heavy chain variable (V(H)) domain framework (FR) residues. Substitution of the FR cavity V(H) Lys-19 residue by an Ala residue resulted in attenuated binding of the 421-433 region peptide probe. The CDRs and V(H) FR replacement/silent mutation ratios exceeded the ratio for a random mutation process, suggesting adaptive development of both putative binding sites. All mAbs studied were derived from V(H)1 family genes, suggesting biased recruitment of the V gene germ line repertoire by E-gp120. The conserved 421-433 region of gp120 is essential for HIV binding to host CD4 receptors. This region is recognized weakly by the FR of antibodies produced without exposure to HIV, but it usually fails to induce adaptive synthesis of neutralizing antibodies. We present models accounting for improved CD4-binding site recognition and broad HIV neutralizing activity of the mAbs, long sought goals in HIV vaccine development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19726674      PMCID: PMC2781617          DOI: 10.1074/jbc.M109.032185

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  85 in total

1.  The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.

Authors:  Susan Zolla-Pazner; Ping Zhong; Kathy Revesz; Barbara Volsky; Constance Williams; Phillipe Nyambi; Miroslaw K Gorny
Journal:  AIDS Res Hum Retroviruses       Date:  2004-11       Impact factor: 2.205

2.  Structural basis of the gp120 superantigen-binding site on human immunoglobulins.

Authors:  S Karray; L Juompan; R C Maroun; D Isenberg; G J Silverman; M Zouali
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

3.  Identification of the B cell superantigen-binding site of HIV-1 gp120.

Authors:  S Karray; M Zouali
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.

Authors:  J P Moore; J Sodroski
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

5.  Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Authors:  Peter B Gilbert; Michael L Peterson; Dean Follmann; Michael G Hudgens; Donald P Francis; Marc Gurwith; William L Heyward; David V Jobes; Vladimir Popovic; Steven G Self; Faruk Sinangil; Donald Burke; Phillip W Berman
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

6.  HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Authors:  G J Gorse; L Corey; G B Patel; M Mandava; R H Hsieh; T J Matthews; M C Walker; M J McElrath; P W Berman; M M Eibl; R B Belshe
Journal:  AIDS Res Hum Retroviruses       Date:  1999-01-20       Impact factor: 2.205

7.  Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection.

Authors:  L Juompan; P Lambin; M Zouali
Journal:  FASEB J       Date:  1998-11       Impact factor: 5.191

8.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

9.  The antigenic structure of the HIV gp120 envelope glycoprotein.

Authors:  R Wyatt; P D Kwong; E Desjardins; R W Sweet; J Robinson; W A Hendrickson; J G Sodroski
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

10.  Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Authors:  James M Binley; Terri Wrin; Bette Korber; Michael B Zwick; Meng Wang; Colombe Chappey; Gabriela Stiegler; Renate Kunert; Susan Zolla-Pazner; Hermann Katinger; Christos J Petropoulos; Dennis R Burton
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more
  9 in total

1.  Constitutive production of catalytic antibodies to a Staphylococcus aureus virulence factor and effect of infection.

Authors:  Eric L Brown; Yasuhiro Nishiyama; Jesse W Dunkle; Shreya Aggarwal; Stephanie Planque; Kenji Watanabe; Keri Csencsits-Smith; M Gabriela Bowden; Sheldon L Kaplan; Sudhir Paul
Journal:  J Biol Chem       Date:  2012-02-02       Impact factor: 5.157

2.  Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.

Authors:  Stephanie A Planque; Yukie Mitsuda; Vida Chitsazzadeh; Santhi Gorantla; Larisa Poluektova; Yasuhiro Nishiyama; Christina Ochsenbauer; Mary-Kate Morris; Gopal Sapparapu; Carl V Hanson; Richard J Massey; Sudhir Paul
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

3.  Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection.

Authors:  Stephanie Planque; Maria Salas; Yukie Mitsuda; Marcin Sienczyk; Miguel A Escobar; Jason P Mooney; Mary-Kate Morris; Yasuhiro Nishiyama; Dipanjan Ghosh; Amit Kumar; Feng Gao; Carl V Hanson; Sudhir Paul
Journal:  AIDS       Date:  2010-03-27       Impact factor: 4.177

Review 4.  Back to the future: covalent epitope-based HIV vaccine development.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama; Miguel Escobar; Carl Hanson
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

5.  Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine.

Authors:  Stephanie A Planque; Yukie Mitsuda; Yasuhiro Nishiyama; Sangeeta Karle; Stephane Boivin; Maria Salas; Mary-Kate Morris; Mariko Hara; Guangling Liao; Richard J Massey; Carl V Hanson; Sudhir Paul
Journal:  J Immunol       Date:  2012-10-22       Impact factor: 5.422

6.  Physiological IgM class catalytic antibodies selective for transthyretin amyloid.

Authors:  Stephanie A Planque; Yasuhiro Nishiyama; Mariko Hara; Sari Sonoda; Sarah K Murphy; Kenji Watanabe; Yukie Mitsuda; Eric L Brown; Richard J Massey; Stanley R Primmer; Brian O'Nuallain; Sudhir Paul
Journal:  J Biol Chem       Date:  2014-03-19       Impact factor: 5.157

7.  Evaluation of the potency of the anti-idiotypic antibody Ab2/3H6 mimicking gp41 as an HIV-1 vaccine in a rabbit prime/boost study.

Authors:  Alexander Mader; Renate Kunert
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

Review 8.  Neutralizing antibodies to HIV-1 induced by immunization.

Authors:  Laura E McCoy; Robin A Weiss
Journal:  J Exp Med       Date:  2013-02-11       Impact factor: 14.307

9.  CD4 binding determinant mimicry for HIV vaccine design.

Authors:  Yasuhiro Nishiyama; Stephanie Planque; Carl V Hanson; Richard J Massey; Sudhir Paul
Journal:  Front Immunol       Date:  2012-12-17       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.